EG 427

EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy... Our first targets in the peripheral nervous system are Type C sensory neurons. Our lead asset, EG110A, targeting these neurons, is in clinical development for the treatment of neurogenic bladder dysfunction, also called NDO. EG 427 received IND clearance from the U.S. FDA for its first-in-human study with EG110A in NDO in June 2024. Our revolutionary approach to the treatment of NDO aims to provide patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular surgery approach overcoming the significant drawbacks of the current standard of care... We are passionate about making a difference for patients with severe chronic diseases. We are developing a powerful DNA medicine platform, and the critical manufacturing infrastructure, to do this.

Primary location: Paris France